The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Abstract
Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding. Crystallographic studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements. BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants. BMS-354825 prolongs survival of mice with BCR-ABL–driven disease and inhibits proliferation of BCR-ABL–positive bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML. These data illustrate how molecular insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationO'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Self-citationMolecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Cited by
Items 101–148 of 148
Cortes, J., Jabbour, E., Kantarjian, H., Yin, C. C., Shan, J., O'Brien, S., Garcia-Manero, G., Giles, F., Breeden, M., Reeves, N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080838 · Cited by 296
Zhou, T., Commodore, L., Huang, W., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V. M., Shakespeare, W. C., Clackson, T., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01054.x · Cited by 287
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 284
Cardiotoxicity induced by tyrosine kinase inhibitors
Orphanos, G. S., Ioannidis, G. N., & Ardavanis, A. G. (2009) · Acta Oncologica · doi:10.1080/02841860903229124 · Cited by 284
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
Jabbour, E., & Kantarjian, H. (2022) · American Journal of Hematology · doi:10.1002/ajh.26642 · Cited by 281
Jabbour, E., Kantarjian, H., Ravandi, F., Thomas, D., Huang, X., Faderl, S., Pemmaraju, N., Daver, N., Garcia-Manero, G., Sasaki, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00207-7 · Cited by 281
Levine, R. L., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2008-03-077966 · Cited by 279
Day, E., Waters, B., Spiegel, K., Alnadaf, T., Manley, P. W., Buchdunger, E., Walker, C., & Jarai, G. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.014 · Cited by 277
Young, M. A., Shah, N. P., Chao, L. H., Seeliger, M., Milanov, Z. V., Biggs, W. H., Treiber, D. K., Patel, H. K., Zarrinkar, P. P., Lockhart, D. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2788 · Cited by 276
Self-citationKobayashi, S., Ji, H., Yuza, Y., Meyerson, M., Wong, K.-K., Tenen, D. G., & Halmos, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1346 · Cited by 272
Shah, N. P., Lee, F. Y., Luo, R., Jiang, Y., Donker, M., & Akin, C. (2006) · Blood · doi:10.1182/blood-2005-10-3969 · Cited by 273
Self-citationHu, Y., Swerdlow, S., Duffy, T. M., Weinmann, R., Lee, F. Y., & Li, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606509103 · Cited by 271
Self-citationBauer, S., Duensing, A., Demetri, G. D., & Fletcher, J. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210558 · Cited by 266
Milojkovic, D., & Apperley, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 265
A conserved protonation-dependent switch controls drug binding in the Abl kinase
Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. Ø., Dror, R. O., Kuriyan, J., & Shaw, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811223106 · Cited by 262
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Hantschel, O., Rix, U., & Superti-Furga, G. (2008) · Leukemia & Lymphoma · doi:10.1080/10428190801896103 · Cited by 256
Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
Sos, M. L., Michel, K., Zander, T., Weiss, J., Frommolt, P., Peifer, M., Li, D., Ullrich, R., Koker, M., Fischer, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37127 · Cited by 258
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., & Cortes, J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-12-200612190-00008 · Cited by 256
Sos, M. L., Fischer, S., Ullrich, R., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 254
Ba/F3 cells and their use in kinase drug discovery
Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a25f · Cited by 240
Chromosomal Abnormalities in Cancer
Fröhling, S., & Döhner, H. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0803109 · Cited by 229
Metabolism and disposition of dasatinib after oral administration to humans
Christopher, L. J., Cui, D., Wu, C., Luo, R., Manning, J. A., Bonacorsi, S. J., Lago, M., Allentoff, A., Lee, F. Y. F., McCann, B., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018267 · Cited by 202
Self-citationDrugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Apperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3339 · Cited by 194
Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation
Ottis, P., Toure, M., Cromm, P. M., Ko, E., Gustafson, J. L., & Crews, C. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00485 · Cited by 176
Advances in imaging mouse tumour models in vivo
Lyons, S. K. (2005) · The Journal of Pathology · doi:10.1002/path.1697 · Cited by 174
Kancha, R. K., von Bubnoff, N., Peschel, C., & Duyster, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1757 · Cited by 168
Luo, F. R., Yang, Z., Camuso, A., Smykla, R., McGlinchey, K., Fager, K., Flefleh, C., Castaneda, S., Inigo, I., Kan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1112 · Cited by 151
Self-citationBewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., & Hazlehurst, L. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0314 · Cited by 150
Kantarjian, H., Jabbour, E., Grimley, J., & Kirkpatrick, P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2135 · Cited by 149
Exploration of databases and methods supporting drug repurposing: a comprehensive survey
Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa003 · Cited by 131
Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations
Johnson, A. R., Kohli, P. B., Katewa, A., Gogol, E., Belmont, L. D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00480 · Cited by 137
Naqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., et al. (2020) · Cancer · doi:10.1002/cncr.32504 · Cited by 135
Zhao, Q., Ren, C., Liu, L., Chen, J., Shao, Y., Sun, N., Sun, R., Kong, Y., Ding, X., Zhang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01264 · Cited by 134
Yip, K. W., Mao, X., Au, P. Y. B., Hedley, D. W., Chow, S., Dalili, S., Mocanu, J. D., Bastianutto, C., Schimmer, A., & Liu, F.-F. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0536 · Cited by 99
Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib
Levêque, D., Becker, G., Bilger, K., & Natarajan-Amé, S. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00872-4 · Cited by 90
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
Yuza, Y., Glatt, K. A., Jiang, J., Greulich, H., Minami, Y., Woo, M. S., Shimamura, T., Shapiro, G. I., Lee, J. C., Ji, H., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.5.4003 · Cited by 88
Lindauer, M., & Hochhaus, A. (2010) · Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_7 · Cited by 57
La Rosée, P., Martiat, P., Leitner, A., Klag, T., Müller, M. C., Erben, P., Schenk, T., Saussele, S., & Hochhaus, A. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1769-2 · Cited by 50
“Thus, the dogma fueled by murine models of CML that continuous target inhibition is a prerequisite for effective leukemic cell kill can no longer be upheld for dasatinib, which represents a different class of ABLtargeting inhibitors with reduced selectivity and enhanced potency [5, 22, 23].”
BackgroundLai, D., Chen, M., Su, J., Liu, X., Rothe, K., Hu, K., Forrest, D. L., Eaves, C. J., Morin, G. B., & Jiang, X. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8735 · Cited by 47
Berman, E., Jhanwar, S., Hedvat, C., Arcila, M. E., Wahab, O. A., Levine, R., Maloy, M., Ma, W., & Albitar, M. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.08.006 · Cited by 41
Schwarzbich, M.-A., Gutknecht, M., Salih, J., Salih, H. R., Brossart, P., Rittig, S. M., & Grünebach, F. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1096-1 · Cited by 42
“Dasatinib is structurally unrelated to imatinib and has been developed as a dual SRC/ABL inhibitor [30, 32].”
BackgroundChristopher, L. J., Cui, D., Li, W., Barros, A., Arora, V. K., Zhang, H., Wang, L., Zhang, D., Manning, J. A., He, K., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018234 · Cited by 40
“The clinical efficacy of dasatinib has been shown in patients with chronic and accelerated phase CML that is intolerant or resistant to imatinib and in patients with CML in blast crisis (Fricker, 2006; Hampton, 2006).”
BackgroundInfluentialDasatinib dose management for the treatment of chronic myeloid leukemia
Talpaz, M., Saglio, G., Atallah, E., & Rousselot, P. (2018) · Cancer · doi:10.1002/cncr.31232 · Cited by 30
Quantitatively accounting for protein reorganization in computer-aided drug design
Fajer, M., Borrelli, K., Abel, R., & Wang, L. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00009 · Cited by 18
An in-depth review of AI-powered advancements in cancer drug discovery
Le, M. H. N., Nguyen, P. K., Nguyen, T. P. T., Nguyen, H. Q., Tam, D. N. H., Huynh, H. H., Huynh, P. K., & Le, N. Q. K. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167680 · Cited by 15
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Metadata
- Authors
- Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L.
- Venue
- Science
- Published
- 2004-07-16
- Volume
- 305
- Issue
- 5682
- Pages
- 399-401
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2092606584
- Cited by
- 1,796
- References
- 20
- FWCI
- 92.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.